Sinemet CR Related Clinical Trials
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet� (Levodopa/Carbidopa) [Completed]
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease [Completed]
A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet� in Parkinson's Disease Subjects [Completed]
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects [Completed]
Antipsychotic Augmentation With L-Dopa [Recruiting]
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD). [Completed]
Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study [Completed]
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 [Completed]
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease [Completed]
Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects [Withdrawn]
A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa [Completed]
A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects [Completed]
Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration [Completed]
Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease [Completed]
Carbidopa-Levodopa Extended-Release (CD-LD ER) Alone or in Combination With Carbidopa-Levodopa Immediate Release (IR) to IPX066 Followed by Extension Safety Study of IPX066 in Subjects With Advanced Parkinson's Disease [Completed]
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects [Completed]
A Study to Assess the Safety and Efficacy of Levodopa Carbidopa Intestinal Gel for the Treatment of Non-motor Symptoms in Subjects With Advanced Parkinson's Disease [Active, not recruiting]
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects [Completed]
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects [Completed]
The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease [Completed]
Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa [Recruiting]
Health Related Quality of Life in Levodopa-carbidopa Intestinal Gel Participants and Levodopa-carbidopa Intestinal Gel Eligible Participants Continuing Oral Therapy [Recruiting]
Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease [Completed]
Effect of Serotonin and Levodopa in Ischemic Stroke [Recruiting]
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy [Completed]
Levodopa Carbidopa Intestinal Gel Home Titration Using Telemedicine: Evaluation of Use of Resources [Completed]
Levodopa Concentration Profile With Stalevo 75/125 mg [Completed]
A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease [Completed]
Comparison of IPX054, Immediate-Release Carbidopa-Levodopa, and Controlled-Release Carbidopa-Levodopa in Subjects With Parkinson's Disease [Completed]
INfusion VErsus STimulation in Parkinson's Disease [Recruiting]
Pharmacokinetic Study in Healthy Males [Completed]
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's [Completed]
High and Low Dose Treatment of Carbidopa in Parkinson's Disease [Completed]
Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations [Completed]
PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding [Terminated]
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa [Completed]
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa [Completed]
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD [Active, not recruiting]
Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence [Recruiting]
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease. [Terminated]
Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients [Completed]
Influence of Theta Burst Stimulation and Carbidopa-Levodopa on Motor Performance in Stroke Patients [Completed]
Erythromycin in Parkinson's Disease [Recruiting]
A Study to Assess the PK and Pharmacodynamics (PD) of IPX203 in Patients With Advanced Parkinsons Disease [Not yet recruiting]
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes [Completed]
PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets [Completed]
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease [Completed]
Neurobiological Principles Applied to the Rehabilitation of Stroke Patients [Recruiting]
Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome [Completed]
Timing of Levodopa Treatment in Parkinson's Disease [Completed]
Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence [Completed]
Vision Response to Dopamine Replacement [Recruiting]
Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease [Completed]
Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse [Recruiting]
PharmacoMRI of Parkinson Disease [Completed]
Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation [Not yet recruiting]
Effect of L-dopa In Subacute Back Pain Population [Recruiting]
A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 [Completed]
Augmenting Language Therapy for Aphasia: Levodopa [Completed]
Use of Zolpidem in Parkinson's Disease [Withdrawn]
A Trial of Levodopa in Angelman Syndrome [Completed]
Substance Abuse Pre-Treatment Screening Study [Recruiting]
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy [Completed]
Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study [Recruiting]
Dopaminergic Modulation of Cognition and Psychomotor Function [Completed]
Treatment of Orthostatic Hypotension in Autonomic Failure [Recruiting]
Effects of Talampanel on Patients With Advanced Parkinson's Disease [Completed]
Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury [Completed]
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) [Completed]
A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease [Completed]
Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease [Completed]
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide [Completed]
The Effect of Dopamine on Motor Skills Training [Completed]
DAPHNE (Duodopa in Advanced Parkinson's: Health Outcomes & Net Economic Impact) [Completed]
A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients [Recruiting]
Talampanel to Treat Parkinson's Disease [Completed]
KW-6002 to Treat Parkinson's Disease [Completed]
Riluzole to Treat Parkinson's Disease [Completed]
ACP-103 to Treat Parkinson's Disease [Completed]
EMD 128130 for the Treatment of Parkinson's Disease [Completed]
Levetiracetam Treatment of L-Dopa Induced Dyskinesias [Completed]
JP-1730 to Treat Parkinson's Disease [Completed]
Lisuride Patch to Treat Parkinson's Disease [Completed]
Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease [Completed]
Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients [Not yet recruiting]
An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications [Active, not recruiting]
A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications [Completed]
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease [Completed]
Study of LY300164 for the Treatment of Parkinson's Disease [Completed]
Relationship of Dopamine to Cognitive Function in Parkinson's Disease [Completed]
50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease [Completed]
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off [Withdrawn]
Medications for Stopping Cocaine Dependence and Preventing Relapse [Recruiting]
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics [Completed]
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease [Completed]
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study) [Completed]
|